Abstract
Background
Intravenous thrombolysis with rt–PA improves outcome in acute ischemic stroke. In a prospective study we analyzed the annual frequency of rt–PA treatment, its safety, and early clinical outcome.
Methods
All patients admitted to our stroke unit (SU) from 1998 to 2003 were registered in a prospective data base. Documented data included patient age, sex, time interval until admission, initial therapy (e. g., thrombolysis), death, intracerebral hemorrhage, other complications, and score on the National Institute of Health Stroke Scale (NIHSS).
Results
From 1998 to 2003, a total of 112 patients were treated with systemic thrombolysis. The number of acute stroke patients admitted within 2.5 hours and therefore eligible for thrombolysis did not substantially change between 1998 and 2003. From 1998 to 2001 the percentage of acute stroke patients that received rt–PA was stable (12.6–16.9 %). This percentage increased in 2002 (29.6%, p<0.05) and, again, in 2003 (42.1%, p<0.01). Of all treated patients, two developed symptomatic intracerebral hemorrhage (1.8%) and five died three to seven days after thrombolysis (4.5 %). The NIHSS score of patients receiving rt–PA significantly decreased during the acute treatment phase (14.2±5.1 to 8.0±5.9, p<0.001). A comparison of single years revealed that this NIHSS score reduction was stable.
Conclusion
In our selected patients, the proportion of acute stroke patients treated with systemic thrombolysis increased almost three–fold from 1998 to 2003. This may be explained by protocol modifications and growing experience with the use of rt–PA. Our data demonstrate that increased use of rt–PA in acute stroke patients can be achieved without adversely affecting safety or clinical benefit.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA (2000) Intravenous tissue–type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 283:1145–1150
Dijkhuizen RM, Asahi M, Wu O, Rosen BR, Lo EH (2002) Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke 33:2100–2104
Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou–Chebl A, Nadzam DM (2004) Cleveland Clinic Health System Stroke Quality Improvement Team. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 61:346–350
Kwan J, Hand P, Sandercock P (2004) A systematic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 33:116–121
The National Institute of Neurological Disorders and Stroke rt–PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587
Pfefferkorn T, Rosenberg GA (2003) Closure of the blood–brain barrier by matrix metalloproteinase inhibition reduces rtPA–mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34:2025–2030
Schenkel J, Weimar C, Knoll T, Haberl RL, Busse O, Hamann GF, Koennecke HC, Diener HC (2003) German Stroke Data Bank Collaborators R1 – systemic thrombolysis in German stroke units – the experience from the German stroke data bank. J Neurol 250:320–324
Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA (1998) Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild–type and tPA–deficient mice. Nat Med 4:228–231
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pfefferkorn, T., Liebetrau, M., Müllner, A. et al. Increasing use of intravenous rt–PA does not affect safety in acute stroke. J Neurol 252, 1500–1503 (2005). https://doi.org/10.1007/s00415-005-0899-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0899-4